Place actuelle des anticoagulants oraux directs dans la maladie thromboembolique veineuse

De Martino, 2012, A meta-analysis of anticoagulation for calf deep venous thrombosis, J Vasc Surg, 56, 228, 10.1016/j.jvs.2011.09.087 Masuda, 2012, The controversy of managing calf vein thrombosis, J Vasc Surg, 55, 550, 10.1016/j.jvs.2011.05.092 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 The EINSTEIN–PE Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572 Prins, 2013, Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies, Thromb J, 11, 21, 10.1186/1477-9560-11-21 Schulman, 2014, Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, 764, 10.1161/CIRCULATIONAHA.113.004450 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 van der Hulle, 2014, Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis, J Thromb Haemost, 12, 320, 10.1111/jth.12485 Steffel, 2018, The 2018 European Heart Rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 Sanchez, 2019, Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l’adulte. Version courte, Rev Mal Respir, 36, 249, 10.1016/j.rmr.2019.01.003 Konstantinides, 2020, 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS), Eur Heart J, 41, 543, 10.1093/eurheartj/ehz405 Chew, 2006, Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med, 166, 458, 10.1001/archinte.166.4.458 Khorana, 2007, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy, J Thromb Haemost, 5, 632, 10.1111/j.1538-7836.2007.02374.x Timp, 2013, Epidemiology of cancer-associated venous thrombosis, Blood, 122, 1712, 10.1182/blood-2013-04-460121 Hutten, 2000, Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis, J Clin Oncol, 18, 3078, 10.1200/JCO.2000.18.17.3078 Prandoni, 2002, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, 3484, 10.1182/blood-2002-01-0108 Lee, 2003, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Young, 2018, Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D), J Clin Oncol, 36, 2017, 10.1200/JCO.2018.78.8034 McBane, 2020, Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial, J Thromb Haemost, 18, 411, 10.1111/jth.14662 Agnelli, 2018, Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: The Caravaggio study, Thromb Haemost, 118, 1668, 10.1055/s-0038-1668523 Schulman, 2015, Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer, Thromb Haemost, 114, 150, 10.1160/TH14-11-0977 Farge, 2019, 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, 20, e566, 10.1016/S1470-2045(19)30336-5 Key, 2020, Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update, J Clin Oncol, 38, 496, 10.1200/JCO.19.01461 Bellesoeur, 2018, Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences, Crit Rev Oncol Hematol, 129, 102, 10.1016/j.critrevonc.2018.06.015 Bapat, 2014, Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta, Obstet Gynecol, 123, 1256, 10.1097/AOG.0000000000000277 Bapat, 2015, Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am J Obstet Gynecol, 213, 710e1, 10.1016/j.ajog.2015.06.065 Cohen, 2016, Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH, J Thromb Haemost, 14, 1673, 10.1111/jth.13366 Goldhaber, 2016, Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER ®, RE-COVER™ II, and RE-MEDY™, Vasc Med, 21, 506, 10.1177/1358863X16668588 Zuily, 2020, Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost, 18, 2126, 10.1111/jth.14935 Cohen, 2016, Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, Lancet Haematol, 3, e426, 10.1016/S2352-3026(16)30079-5 Pengo, 2018, Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome, Blood, 132, 1365, 10.1182/blood-2018-04-848333 Ordi-Ros, 2019, Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial, Ann Intern Med, 171, 685, 10.7326/M19-0291 Sanchez-Redondo, 2019, Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and meta-analysis, Clin Ther, 41, 1839, 10.1016/j.clinthera.2019.06.015 Dufrost, 2018, Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysiS, Autoimmun Rev, 17, 1011, 10.1016/j.autrev.2018.04.009 Tektonidou, 2019, EULAR recommendations for the management of antiphospholipid syndrome in adults, Ann Rheum Dis, 78, 1296, 10.1136/annrheumdis-2019-215213 Skelley, 2017, The use of direct oral anticoagulants in inherited thrombophilia, J Thromb Thrombolysis, 43, 24, 10.1007/s11239-016-1428-2 Alameddine, 2020, Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants, Thromb Res, 185, 72, 10.1016/j.thromres.2019.11.008 Elsebaie, 2019, Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis, J Thromb Haemost, 17, 645, 10.1111/jth.14398 Hindricks, 2021, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, 42, 373, 10.1093/eurheartj/ehaa612 Upreti, 2013, Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects: effect of extremes of body weight on the PK/PD of apixaban, Br J Clin Pharmacol, 76, 908, 10.1111/bcp.12114 Kubitza, 2007, Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects, J Clin Pharmacol, 47, 218, 10.1177/0091270006296058 Barsam, 2017, The impact of body weight on rivaroxaban pharmacokinetics, Res Pract Thromb Haemost, 1, 180, 10.1002/rth2.12039 Martin, 2021, Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study, Thromb Haemost, 121, 224, 10.1055/s-0040-1715834 Nisio, 2016, Treatment of venous thromboembolism with rivaroxaban in relation to body weight: A sub-analysis of the EINSTEIN DVT/PE studies, Thromb Haemost, 116, 739, 10.1160/TH16-02-0087 Wang, 2020, antagonist oral anticoagulant for atrial fibrillation in obese Patients, Am J Cardiol, 127, 176, 10.1016/j.amjcard.2020.04.016 Hohnloser, 2019, Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: insights from the ARISTOTLE trial, Circulation, 139, 2292, 10.1161/CIRCULATIONAHA.118.037955 Rocca, 2018, Antithrombotic therapy and body mass: an expert position paper of the ESC Working group on Thrombosis, Eur Heart J, 39, 1672, 10.1093/eurheartj/ehy066 Pandey, 2021, Direct oral anticoagulant dosing in extremes of body weight: time to revisit the guidelines?, Thromb Haemost, 121, 118, 10.1055/s-0040-1716753 Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541 Weitz, 2017, Rivaroxaban or aspirin for extended treatment of venous thromboembolism, N Engl J Med, 376, 1211, 10.1056/NEJMoa1700518 Brighton, 2012, Low-dose aspirin for preventing recurrent venous thromboembolism, N Engl J Med, 367, 1979, 10.1056/NEJMoa1210384 Becattini, 2012, Aspirin for preventing the recurrence of venous thromboembolism, N Engl J Med, 366, 1959, 10.1056/NEJMoa1114238 Schulman, 2013, Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, N Engl J Med, 368, 709, 10.1056/NEJMoa1113697